The Comparative Advantage of the Optrell Mapping Catheter in Ventricular Arrhythmias From the Papillary Muscles
1 other identifier
observational
20
1 country
1
Brief Summary
We believe that the design of the Optrell™ mapping catheter with TRUEref technology allows for faster and more accurate mapping not only due to narrow electrode spacing but also due to the ability to achieve simultaneous contact of multiple bipoles with the surface of the papillary muscle. Simultaneous mapping of multiple sites on the same surface will allow operators to appreciate small activation differences that typically exist between neighboring sites during papillary muscle ventricular arrhythmias. In addition, the position of the Optrell™ mapping catheter on the papillary muscle allows the mapping catheter to move with the papillary muscle rendering a more accurate allocation of the activation time to the surface of the papillary muscle. We also believe that optimal positioning between the Optrell™ mapping catheter and papillary muscles can be assisted by using intracardiac echocardiography. The goal of the study is to explore the utility and superiority of a specific mapping catheter, the Optrell™ mapping catheter with TRUEref.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 30, 2024
CompletedFirst Submitted
Initial submission to the registry
May 14, 2025
CompletedFirst Posted
Study publicly available on registry
April 21, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2028
April 21, 2026
April 1, 2026
4 years
May 14, 2025
April 17, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Evaluate acute success in eliminating premature ventricular contractions
During procedure
Evaluate success at 3 months follow up in eliminating premature ventricular contractions
At 3 months follow post-procedure
Interventions
The Optrell™ mapping catheter with TRUEref technology is device that is used as an option during ablation of premature ventricular contractions originating from the papillary muscles.
Eligibility Criteria
Patients aged 18-75 diagnosed with ventricular arrhythmias.
You may qualify if:
- Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements
- Patient is not cognitively impaired, pregnant, prisoner, employed by Northwell, uninsured, or a student
- Age 18-75 years old with the ability to consent for the procedure
- Patient is consented within the enrollment window of the therapy received, as applicable
- Patients with frequent (\>10%) or symptomatic PVCs with ECG morphology consistent with papillary muscle origin.
- Papillary muscle PVCs in setting of cardiomyopathy.
- Patients prescribed by their treating physician to undergo the procedure with the Optrell™ mapping catheter as part of routine clinical care.
- Patient demonstrates proficiency in the English language; reading, writing, and conversational
You may not qualify if:
- Patient who is, or is expected to be, inaccessible for follow-up
- Participation is excluded by local law
- Patient is currently enrolled or plans to enroll in concurrent drug/device study that may confound the study results
- Unable to consent
- PVC from site other than papillary muscle
- Acute coronary syndrome
- Congestive heart failure in acute decompensation
- Rapid atrial fibrillation
- Requiring ventricular pacing
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Northwell Healthlead
Study Sites (1)
Long Island Jewish Medical Center
New Hyde Park, New York, 11040, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Haisam Ismail, MD
Northwell Health
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 14, 2025
First Posted
April 21, 2026
Study Start
December 30, 2024
Primary Completion (Estimated)
December 30, 2028
Study Completion (Estimated)
December 30, 2028
Last Updated
April 21, 2026
Record last verified: 2026-04